Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PM2PM4PP5_Very_Strong
The NM_007294.4(BRCA1):c.5558_5559insA(p.Tyr1853Ter) variant causes a stop gained, frameshift change. The variant allele was found at a frequency of 0.00000124 in 1,613,762 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. Y1853Y) has been classified as Uncertain significance.
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
Verdict is Pathogenic. Variant got 12 ACMG points.
PM2
?
PM2 - Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium
Very rare variant in population databases, with high coverage;
PM4
?
PM4 - Protein length changes as a result of in-frame deletions/insertions in a nonrepeat region or stop-loss variants
Frameshift in the end of transcript resulting in stoplost. Downstream stopcodon found after 2152 codons.
PP5
?
PP5 - Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation
Variant 17-43045711-G-GT is Pathogenic according to our data. Variant chr17-43045711-G-GT is described in ClinVar as [Pathogenic]. Clinvar id is 55628.Status of the report is reviewed_by_expert_panel, 3 stars.
Breast-ovarian cancer, familial, susceptibility to, 1 Pathogenic:6
Pathogenic, criteria provided, single submitter
clinical testing
Baylor Genetics
Jan 19, 2023
- -
Pathogenic, no assertion criteria provided
clinical testing
Breast Cancer Information Core (BIC) (BRCA1)
May 29, 2002
- -
Pathogenic, criteria provided, single submitter
clinical testing
Counsyl
Apr 07, 2016
- -
Pathogenic, no assertion criteria provided
literature only
OMIM
Dec 01, 1994
- -
Pathogenic, no assertion criteria provided
clinical testing
Sharing Clinical Reports Project (SCRP)
May 01, 2012
- -
Pathogenic, reviewed by expert panel
curation
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA)
Sep 08, 2016
Variant allele predicted to encode a truncated non-functional protein. -
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter
clinical testing
Revvity Omics, Revvity
Nov 03, 2022
- -
Pathogenic, criteria provided, single submitter
clinical testing
GeneDx
Oct 20, 2022
Nonsense variant predicted to result in protein truncation in a gene for which loss-of-function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Truncating variants in this gene are considered pathogenic by a well-established clinical consortium and/or database; Also known as 5677dupA; This variant is associated with the following publications: (PMID: 21922593, 20104584, 7894493, 8942979, 14534301, 7795652, 27802165, 10811118, 12400015, 28392550, 25186627, 24728189, 18992264, 31013702, 24504028, 30787465, 30765603, 34439109, Levine[case report], 32322110, 33237286) -
Pathogenic, criteria provided, single submitter
clinical testing
Clinical Genetics and Genomics, Karolinska University Hospital
May 25, 2016
- -
Pathogenic, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Sep 07, 2017
- -
Hereditary breast ovarian cancer syndrome Pathogenic:3
Pathogenic, no assertion criteria provided
research
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto
Jan 31, 2014
- -
Pathogenic, criteria provided, single submitter
clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Apr 02, 2021
Variant summary: BRCA1 c.5558dupA (p.Tyr1853X) results in a premature termination codon, predicted to cause a truncation of the encoded protein The variant was absent in 253430 control chromosomes (gnomAD). c.5558dupA has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer Syndrome (example: Song_2014, Judkins_2005) and also has been found to co-segregate within a large affected family (Friedman_1994). These data indicate that the variant is very likely to be associated with disease. In functional studies, the variant has been found to reduce transcriptional activity (Carvalho_2007). Eight ClinVar submitters (evaluation after 2014) including an expert panel (ENIGMA) cite the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. -
Pathogenic, criteria provided, single submitter
clinical testing
Invitae
Jan 17, 2024
This sequence change creates a premature translational stop signal (p.Tyr1853*) in the BRCA1 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 11 amino acid(s) of the BRCA1 protein. This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and/or ovarian cancer (PMID: 7894493, 20104584, 24504028). It has also been observed to segregate with disease in related individuals. This variant is also known as (c.5677insA, Y1853_L1854delinsX). ClinVar contains an entry for this variant (Variation ID: 55628). Algorithms developed to predict the effect of variants on protein structure and function are not available or were not evaluated for this variant. Experimental studies have shown that this premature translational stop signal affects BRCA1 function (PMID: 10811118, 11739404, 12400015, 21922593). For these reasons, this variant has been classified as Pathogenic. -
This variant is located in the BRCA1 protein. Splice site prediction tools suggest that this variant may not impact RNA splicing. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Pathogenic. -
Pathogenic, criteria provided, single submitter
clinical testing
Ambry Genetics
Oct 04, 2021
The c.5558dupA pathogenic mutation, located in coding exon 22 of the BRCA1 gene, results from a duplication of A at nucleotide position 5558, causing a translational frameshift with a predicted alternate stop codon (p.Y1853*). This alteration occurs at the 3' terminus of theBRCA1 gene, is not expected to trigger nonsense-mediated mRNA decay, and only impacts the last 11 amino acids of the protein. However, premature stop codons are typically deleterious in nature and the impacted region is critical for protein function (Ambry internal data). This mutation has been identified in multiple individuals with Hereditary Breast and Ovarian Cancer (HBOC) syndrome (Friedman et al. Nat. Genet. 1994 Dec;8(4):399-404; Borg et al. Hum. Mutat. 2010 Mar;31(3):E1200-40; Song H et al. Hum. Mol. Genet. 2014 Sep;23(17):4703-9; Tung N et al. Cancer, 2015 Jan;121:25-33), and has been shown to cause loss of function in functional assays (Hayes et al. Cancer Res. 2000 May;60(9):2411-8). Of note, this alteration is also designated as 5677insA in published literature. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -